Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
PACCAR Inc. (PCAR) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PACCAR Inc. (PCAR) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for January 26th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 26:
PACCAR Inc (PCAR - Free Report) : This truck manufacturer company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.1% over the last 60 days.
PACCAR Inc. Price and Consensus
PACCAR Inc. price-consensus-chart | PACCAR Inc. Quote
PACCAR's shares gained 22.5% over the last three months compared with the S&P 500’s advance of 18%. The company possesses a Momentum Score of A.
PACCAR Inc. Price
PACCAR Inc. price | PACCAR Inc. Quote
Inhibikase Therapeutics, Inc. (IKT - Free Report) : This pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16% over the last 60 days.
Inhibikase Therapeutics, Inc. Price and Consensus
Inhibikase Therapeutics, Inc. price-consensus-chart | Inhibikase Therapeutics, Inc. Quote
Inhibikase Therapeutics's shares gained 195.5% over the last three months compared with the S&P 500’s advance of 18%. The company possesses a Momentum Score of A.
Inhibikase Therapeutics, Inc. Price
Inhibikase Therapeutics, Inc. price | Inhibikase Therapeutics, Inc. Quote
PagerDuty, Inc. (PD - Free Report) : This digital operations platform company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16.1% over the last 60 days.
PagerDuty Price and Consensus
PagerDuty price-consensus-chart | PagerDuty Quote
PagerDuty's shares gained 21.8% over the last three months compared with the S&P 500’s advance of 18%. The company possesses a Momentum Score of B.
PagerDuty Price
PagerDuty price | PagerDuty Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.